肺表面活性物质治疗新生儿肺透明膜病的疗效观察

目的：观察肺表面活性物质治疗新生儿肺透明膜病的疗效。方法参照组患儿均送入新生儿CCU病房实施重症监护。给予其常规的保暖、静脉营养、感染防控、水电及酸碱平衡维系及其他相应对症治疗，同时应用CPAP辅助呼吸治疗。临床组在参照组的常规治疗方案及CPAP辅助呼吸的基础上，额外应用肺表面活性物质进行治疗。比照两组临床疗效及血气指标中血液pH、PaO2及PaCO2的治疗前后改善情况。最后统计两组CPAP呼吸辅助总时长及吸氧总时长。结果临床组总有效率为94.03%，显著高于参照组的71.64%（P＜0.05）。两组治疗前pH、PaO2及PaCO2三个指标相比无显著差异，治疗后均较治疗前相比显著改善（P＜0.05），且临床组其改善幅度显著优于参照组（P＜0.05）。临床组其CPAP呼吸辅助总时长及吸氧总时长均显著少于参照组（P＜0.05）。结论新生儿肺透明膜病应用肺表面活性物质其临床疗效显著，可迅速恢复患儿的自主呼吸功能。

The curative effect of pulmonary surfactant in treatment of neonatal hyaline membrane disease

Objective To observe the therapeutic effect of pulmonary surfactant in treatment of neonatal hyaline membrane disease. Methods The reference group of children were admitted to the neonatal intensive care ward CCU implementation. Given the general warmth, intravenous nutrition, infection control, hydropower and acid-base balance maintenance and other symptomatic treatment, at the same time, application of ventilator assisted breathing CPAP non-invasive ventilator therapy. Clinical group based on routine treatment control group and ventilator application, additional application of pulmonary surfactant treatment. Before and after treatment with pH, PaO2 and PaCO2 blood group of two clinical effect and blood gas indexes to improve the situation. Finally, two sets of statistics CPAP respiratory assist total length, total number of days of mechanical ventilation and oxygen total length. Results The clinical total effective rate was 94.03%, significantly higher than that in control group （P〈0.05） with 71.64%. The two groups before treatment, pH, PaO2 and PaCO2 three indicators showed no significant difference, after treatment than before treatment was compared with the significantly improved （P〈0.05）, and the clinical group was significantly better than the control group significantly improved （P 〈 0.05）. Clinical group the CPAP respiratory assist total length, total number of days of mechanical ventilation and oxygen total duration were significantly less than the reference group （P〈0.05）. Conclusion Pulmonary hyaline membrane disease of newborn and its clinical application of pulmonary surfactant significantly, breathing function can be recovered rapidly in children.